Genetic and Clinical Predictors of Response to Warfarin and Novel Anticoagulants

$684,219R01FY2015HLNIH

University Of Alabama At Birmingham, Birmingham AL

Investigators

Linked publications & trials

Paper 39073889 Paper 38470993 Paper 36306392 Paper 35857814 Paper 35156424 Paper 35034351 Paper 34233023 Paper 33667441 Paper 33428770 Paper 33315113 Paper 33278832 Paper 33276038 Paper 32897581 Paper 32678355 Paper 32363774 Paper 32042096 Paper 31869433 Paper 31786980 Paper 31664775 Paper 31124414 Paper 30894703 Paper 30883405 Paper 30345882 Paper 29393514 Paper 29280137 Paper 29102571 Paper 29057167 Paper 28949423 Paper 28806200 Paper 28686080 Paper 28492415 Paper 28294551 Paper 28198005 Paper 28124392 Paper 27706224 Paper 27531069 Paper 27383664 Paper 27294752 Paper 27241839 Paper 27161037 Paper 26877068 Paper 26482791 Paper 26418204 Paper 26397414 Paper 26265036 Paper 26024874 Paper 25866354 Paper 25791389 Paper 25587093 Paper 25468385 Paper 25079360 Paper 25032265 Paper 24849109 Paper 24454922 Paper 24251361 Paper 24052022 Paper 23819817 Paper 23755828 Paper 23606318 Paper 23159233 Paper 23133417 Paper 22308193 Paper 22308192 Paper 22186998 Paper 21450715 Paper 20709439 Paper 20375999 Paper 20203262 Paper 19995676 Paper 19297219 Paper 19228618 Paper 19225037

Abstract

DESCRIPTION (provided by applicant): Although oral anticoagulant (OAC) therapy provides superior stroke risk reduction in patients with Atrial Fibrillation (AF), it is widely underutilize with hemorrhage being a major deterrent. OAC related hemorrhage accounts for 33.3% of adverse-drug- related hospitalizations in the US and is a critical barrier to institution of therapy. This revised application builds on our successful project identifying the influence of genes on warfarin dose, anticoagulation control, and hemorrhage (n=1310; 43% Black). We expand our efforts to incorporate new OACs to identify predictors of hemorrhage in Dabigatran (DBG; n=500) and warfarin (n=1000; 590 accrued) treated AF patients through four specific aims. Aim 1 will elucidate the influence of common and rare genetic variation on risk of warfarin-related hemorrhage using a genome-wide approach. The discovery efforts will be grounded in 700 warfarin-related hemorrhage case-control pairs with replication in an independent prospective cohort of 1000 warfarin-treated AF patients. Aim 2 will elucidate the influence of race, kidney impairment and concurrent antiplatelet therapy on risk of warfarin-related hemorrhage in the prospective cohort of 1000 warfarin-treated AF patients. Aim 3 will elucidate the influence of kidney impairment and concurrent antiplatelet therapy on risk of warfarin- related hemorrhage in the prospective cohort of 500 DBG-treated AF patients. Aim 4 will incorporate patient-specific genetic and clinical factors into refining (for warfarin) and building (for DBG) clinical predictio rules (CPRs) to personalize the prediction of hemorrhage. The AF patient-cohort will provide a robust foundation for future efforts that will incorporate other new OACs namely rivaroxaban and apixaban. The focus on AF lays the foundation for future real-world comparative- effectiveness evaluation in a population representative of clinical practice.

View original record on NIH RePORTER →